vs

Side-by-side financial comparison of Arcturus Therapeutics Holdings Inc. (ARCT) and Red Cat Holdings, Inc. (RCAT). Click either name above to swap in a different company.

Red Cat Holdings, Inc. is the larger business by last-quarter revenue ($9.6M vs $7.2M, roughly 1.3× Arcturus Therapeutics Holdings Inc.). On growth, Red Cat Holdings, Inc. posted the faster year-over-year revenue change (988.2% vs -68.4%). Red Cat Holdings, Inc. produced more free cash flow last quarter ($-24.5M vs $-74.5M).

Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA (siRNA), messenger RNA (mRNA), gene editing RNA, DNA, antisense oligonucleotides, and microRNA.

Mega Cat Studios is an American video game development and publishing company located in Pittsburgh, Pennsylvania. It was founded in 2015 by James Deighan, Nick Mann, and Zack Manko.

ARCT vs RCAT — Head-to-Head

Bigger by revenue
RCAT
RCAT
1.3× larger
RCAT
$9.6M
$7.2M
ARCT
Growing faster (revenue YoY)
RCAT
RCAT
+1056.6% gap
RCAT
988.2%
-68.4%
ARCT
More free cash flow
RCAT
RCAT
$50.0M more FCF
RCAT
$-24.5M
$-74.5M
ARCT

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
ARCT
ARCT
RCAT
RCAT
Revenue
$7.2M
$9.6M
Net Profit
$-16.0M
Gross Margin
6.6%
Operating Margin
-181.7%
Net Margin
-166.0%
Revenue YoY
-68.4%
988.2%
Net Profit YoY
3.1%
-29.0%
EPS (diluted)
$-0.16

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARCT
ARCT
RCAT
RCAT
Q4 25
$7.2M
Q3 25
$17.2M
$9.6M
Q2 25
$28.3M
Q1 25
$29.4M
$1.6M
Q4 24
$22.8M
$0
Q3 24
$41.7M
Q2 24
$49.9M
Q1 24
$38.0M
$5.8M
Net Profit
ARCT
ARCT
RCAT
RCAT
Q4 25
Q3 25
$-13.4M
$-16.0M
Q2 25
$-9.2M
Q1 25
$-14.1M
$-23.1M
Q4 24
$-30.0M
$-13.3M
Q3 24
$-6.9M
Q2 24
$-17.2M
Q1 24
$-26.8M
$-5.5M
Gross Margin
ARCT
ARCT
RCAT
RCAT
Q4 25
Q3 25
6.6%
Q2 25
Q1 25
-52.2%
Q4 24
Q3 24
Q2 24
Q1 24
18.8%
Operating Margin
ARCT
ARCT
RCAT
RCAT
Q4 25
Q3 25
-96.3%
-181.7%
Q2 25
-41.0%
Q1 25
-57.3%
-765.7%
Q4 24
-146.7%
Q3 24
-25.8%
Q2 24
-42.4%
Q1 24
-80.0%
-76.0%
Net Margin
ARCT
ARCT
RCAT
RCAT
Q4 25
Q3 25
-78.4%
-166.0%
Q2 25
-32.4%
Q1 25
-47.9%
-1418.9%
Q4 24
-131.8%
Q3 24
-16.6%
Q2 24
-34.5%
Q1 24
-70.5%
-93.9%
EPS (diluted)
ARCT
ARCT
RCAT
RCAT
Q4 25
Q3 25
$-0.49
$-0.16
Q2 25
$-0.34
Q1 25
$-0.52
$-0.27
Q4 24
$-1.10
Q3 24
$-0.26
Q2 24
$-0.64
Q1 24
$-1.00

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARCT
ARCT
RCAT
RCAT
Cash + ST InvestmentsLiquidity on hand
$230.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$214.0M
$253.3M
Total Assets
$271.1M
$286.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARCT
ARCT
RCAT
RCAT
Q4 25
$230.9M
Q3 25
$180.4M
Q2 25
$196.5M
Q1 25
$216.9M
Q4 24
$237.0M
Q3 24
$237.2M
Q2 24
$260.3M
Q1 24
$288.4M
Stockholders' Equity
ARCT
ARCT
RCAT
RCAT
Q4 25
$214.0M
Q3 25
$224.6M
$253.3M
Q2 25
$231.1M
Q1 25
$233.8M
$28.9M
Q4 24
$241.0M
$27.0M
Q3 24
$261.9M
Q2 24
$258.6M
Q1 24
$264.0M
$49.6M
Total Assets
ARCT
ARCT
RCAT
RCAT
Q4 25
$271.1M
Q3 25
$282.3M
$286.0M
Q2 25
$309.3M
Q1 25
$331.8M
$59.7M
Q4 24
$344.1M
$51.1M
Q3 24
$370.7M
Q2 24
$388.6M
Q1 24
$418.8M
$55.3M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARCT
ARCT
RCAT
RCAT
Operating Cash FlowLast quarter
$-74.3M
$-23.9M
Free Cash FlowOCF − Capex
$-74.5M
$-24.5M
FCF MarginFCF / Revenue
-1035.2%
-254.2%
Capex IntensityCapex / Revenue
3.2%
6.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-55.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARCT
ARCT
RCAT
RCAT
Q4 25
$-74.3M
Q3 25
$-17.2M
$-23.9M
Q2 25
$-5.8M
Q1 25
$-35.1M
$-15.9M
Q4 24
$-284.0K
$-10.1M
Q3 24
$-23.8M
Q2 24
$-30.1M
Q1 24
$-5.6M
$-4.1M
Free Cash Flow
ARCT
ARCT
RCAT
RCAT
Q4 25
$-74.5M
Q3 25
$-17.3M
$-24.5M
Q2 25
Q1 25
$-35.3M
$-16.2M
Q4 24
$-10.2M
Q3 24
$-23.8M
Q2 24
$-30.5M
Q1 24
$-5.8M
$-4.2M
FCF Margin
ARCT
ARCT
RCAT
RCAT
Q4 25
-1035.2%
Q3 25
-101.1%
-254.2%
Q2 25
Q1 25
-120.1%
-992.9%
Q4 24
Q3 24
-57.2%
Q2 24
-61.1%
Q1 24
-15.3%
-71.1%
Capex Intensity
ARCT
ARCT
RCAT
RCAT
Q4 25
3.2%
Q3 25
1.1%
6.9%
Q2 25
0.0%
Q1 25
0.5%
16.8%
Q4 24
0.0%
Q3 24
0.2%
Q2 24
0.7%
Q1 24
0.6%
0.8%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ARCT
ARCT

Segment breakdown not available.

RCAT
RCAT

Products$8.5M88%
Services$1.2M12%

Related Comparisons